The DEA has recently proposed a new rule for Telemedicine Prescribing of Controlled Substances.

PRINT THIS + Bring To Your Next Primary Care Appointment

Primary Care to Telepsychiatry Referral Letter.pdf

UPDATE: In Late December 2024, the DEA again extended the telemedicine flexibilities while they continue to consider the record 38,000+ comments from the public, largely from people with ADHD who view this new rule as a burden and barrier to care.

Third Extension of Telemedicine Flexibilities for Prescription of Controlled Medications

“DEA addressed the status of telemedicine prescribing flexibilities including state reciprocity (DEA-DC-018 EO-DEA067) and medications for opioid use disorder prescribed by telephone (DEA-DC-022 EO-DEA068) in the temporary rule titled "Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications" which published in the Federal Register on May 10, 2023. 88 FR 30042. With respect to practitioner patient relationships formed after the May 11, 2023, expiration of the COVID–19 PHE, a third temporary rule will extend these exceptions until December 31, 2025”

• This new rule will only go into effect for current patients after December 31st, 2025.
• Your care will continue as normal in the meantime.
• Your appointments and prescriptions will not be affected.

<aside> 📍 ACTION ITEM for Current Patients: Before December 31st, 2025, all patients will need to have an in-person visit with their Primary Care Provider (PCP) for them to sign the ‘Referral Form.’

</aside>

<aside> 📍 Potential Consequence: If we do not receive your signed ‘Telemedicine Referral Form’ by December 31st, 2025, we may no longer be able to prescribe your controlled substances, including stimulant medications, for ADHD.

</aside>

What if I don’t have a Primary Care Provider (PCP)?